Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.
Treatment with at least 90 μg/kg of the novel DLLC-targeting T-cell–engager BI 764532 was well tolerated and led to tumor shrinkage in patients with small cell lung cancer and neuroendocrine carcinoma.
Martin Wermke, MD, discusses why the novel T-cell engager BI 764532 may serve as a promising treatment option targeting DLL3 in small cell lung cancer and neuroendocrine carcinomas .